Intravaginal delivery of biologically active polypeptides

Details Intravaginal delivery of biologically active polypeptides Intravaginal delivery of biologically active polypeptides

1992-06-15

1998-11-24

Tsang, Cecilia J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530324, 530307, A61K 3800, C07K 760, C07K 736, C07K 1400

Patent

active

058406859

ABSTRACT:
Pharmaceutical compositions of matter adapted for intravaginal administration comprise a biologically active polypeptide, an absorption promoter, such as an anionic and/or nonionic surfactant or a nonionic surfactant and an aliphatic carboxylic acid, optionally an animal and/or vegetable protein and a nontoxic pharmaceutically acceptable carrier or diluent therefor, in a formulation suitable for intravaginal administration. Preferred compositions comprise calcitonin as the biologically active polypeptide. Preferred absorption promoters are anionic surfactants, e.g., sodium lauryl sulfate, and the combination absorption promoter of a nonionic surfactant and a medium chain aliphatic carboxylic acid or its salt, e.g. polyoxyethylenealkylphenylether and a medium chain aliphatic carboxylic acid.

REFERENCES:
patent: 3888838 (1975-06-01), Immer et al.
patent: 3917825 (1975-11-01), Matsuzawa et al.
patent: 4010125 (1977-03-01), Schally et al.
patent: 4018726 (1977-04-01), Schally et al.
patent: 4083967 (1978-04-01), Beddell et al.
patent: 4234571 (1980-11-01), Nestor et al.
patent: 4609640 (1986-09-01), Morishita et al.
patent: 4659696 (1987-04-01), Hirai et al.
patent: 4670419 (1987-06-01), Uda et al.
patent: 4690952 (1987-09-01), Kagatani et al.
Azaz et al, Chem. Abst. 96:74626N (1982).
Hirai, International Journal of Pharmaceutical, 174-184, 1981.
Muranishi, "Absorption Barriers and Absorption Promoters in the Intestine", Topics in Pharmaceuticals Sciences (1987), pp. 445-455.
Jerusalem University, IL 54041, "Pharmaceutical composition for enteral or vaginal application" (1981).
Morimoto, et al., "Effect of non-ionic surfactants in a polyacrylic acid Pharm. Pharmacol., vol. 37 (1985), pp. 759-760.
Okada, "Vaginal Administration of a Potent Luteinizing Hormone-Releasing Hormone Analog (Leuprolide)", J. Takeda Res. Lab., 42 (1/2) (1983), pp. 150-208.
Touitou, et al., "New hydrophilic vehicle enabling rectal and vaginal absorption of insulin, heparin, phenol red and gentamicin", J. Pharm. Pharmac., vol. 30 (1978), pp. 662-663.
Saito, et al., "Stimulation of Luteinizing Hormone (LH) and !-LH-Releasing Hormone Ethylamide After Subcutaneous, Intravaginal, and Intrarectal Administration To Women", Fertility and Sterility, vol. 28, No. 3 (1977), pp. 240-245.
Okada, et al., "Vaginal Absdorption of a Potent Luteinizing Hormone-Releasing Hormone Analogoue (Leuprolide) in Rats II: Mechanism of Absorption Enhancement with Organic Acids", Journal of Pharmaceutical Sciences, vol. 72, No. 1 (1983), PP. 75-78.
Okada, Journal of Pharmaceutical Sciences, 71, No. 12, 1366-1371 (1982).

Affiliated with

Also associated with

Rating

Intravaginal delivery of biologically active polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Intravaginal delivery of biologically active polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intravaginal delivery of biologically active polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1702170